Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma

This pilot study assessed the safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794), a genetically modified autologous T-cell therapy targeting New York esophageal squamous cell carcinoma-1 (NY-ESO-1)/L antigen family member 1 isoform A (LAGE-1a)–positive myeloma cells, alone or in c...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishihori, Taiga, Hoffman, James E., Huff, Anne, Kapoor, Gurpreet S., Eleftheriadou, Ioanna, Zajic, Stefan, Urbano, Alisa, Suchindran, Sunil, Chisamore, Michael, D’Souza, Jimson W., Faitg, Thomas, Rapoport, Aaron P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111356/
https://www.ncbi.nlm.nih.gov/pubmed/36534160
http://dx.doi.org/10.1182/bloodadvances.2022008460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111356/
https://www.ncbi.nlm.nih.gov/pubmed/36534160
http://dx.doi.org/10.1182/bloodadvances.2022008460

Ejemplares similares